Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

NCT ID: NCT00955799

Last Updated: 2012-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

455 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subjective Tinnitus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Subjective, Tinnitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neramexane mesylate

Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day

Group Type EXPERIMENTAL

Neramexane mesylate

Intervention Type DRUG

Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day

Placebo

Placebo: identical placebo tablets

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Double-blind treatment period of 29 weeks placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neramexane mesylate

Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day

Intervention Type DRUG

Placebo

Double-blind treatment period of 29 weeks placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged between 18 and 75 years with a clinical diagnosis of first onset, persistent (i.e., tinnitus should never be absent for \> 24 hours in a row), subjective, uni- or bilateral subacute tinnitus

Exclusion Criteria

* Clinical diagnosis of intermittent or pulsatile tinnitus
* Patients who have tinnitus as a concomitant symptom of an otological/neurological disease (such as otitis media, Menière's disease, otosclerosis, etc)
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merz Pharmaceuticals GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Expert

Role: STUDY_DIRECTOR

Merz Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Horizon Clinical Research Associates PLLC

Gilbert, Arizona, United States

Site Status

Phoenix Clinical

Phoenix, Arizona, United States

Site Status

Paradigm Clinical Research

Tucson, Arizona, United States

Site Status

Providence Clinical Research

Burbank, California, United States

Site Status

Central California Clinical Research

Fresno, California, United States

Site Status

UC Davis Health System

Sacramento, California, United States

Site Status

Colorado Otolaryngology Associates

Colorado Springs, Colorado, United States

Site Status

New West Physicians

Golden, Colorado, United States

Site Status

Visions Clinical Research

Boynton Beach, Florida, United States

Site Status

Tampa Bay Medical Research

Clearwater, Florida, United States

Site Status

Clinical Research of West Florida, Inc.

Tampa, Florida, United States

Site Status

Deerpath Physicians Group

Gurnee, Illinois, United States

Site Status

Knight Center for Integrated Health

Peoria, Illinois, United States

Site Status

Deaconess Clinic, Inc.

Evansville, Indiana, United States

Site Status

MediSphere Medical Research Center, LLC

Evansville, Indiana, United States

Site Status

Deaconess Clinic, Inc.

Newburgh, Indiana, United States

Site Status

University of Iowa Hospitals & Clinics

Iowa City, Iowa, United States

Site Status

University of Kansas; Department of Otolaryngology Head & Neck Surgery

Kansas City, Kansas, United States

Site Status

Heartland Research Associates, LLC.

Wichita, Kansas, United States

Site Status

Heartland Research Associates, LLC.

Wichita, Kansas, United States

Site Status

Commonwealth Ear, Nose & Throat

Louisville, Kentucky, United States

Site Status

Glacier Ear, Nose, and Throat, Head and Neck Surgery, P.C.

Kalispell, Montana, United States

Site Status

Immedicenter

Bloomfield, New Jersey, United States

Site Status

David L. Bortniker

Somerville, New Jersey, United States

Site Status

Erie County Medical Center, Department of Rehabilitation Medicine; State University of New York at Buffalo

Buffalo, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

Cary Medical Research

Cary, North Carolina, United States

Site Status

Wake Research Associates, LLC

Raleigh, North Carolina, United States

Site Status

Wilmington Medical Research

Wilmington, North Carolina, United States

Site Status

Piedmont Medical Research

Winston-Salem, North Carolina, United States

Site Status

Medical University of South Carlolina, Otolaryngology

Charleston, South Carolina, United States

Site Status

Austin Ear, Nose and Throat Clinic

Austin, Texas, United States

Site Status

Future Search Trials of Neurology

Austin, Texas, United States

Site Status

FutureSearch Trials of Dallas

Dallas, Texas, United States

Site Status

R/D Clinical Research, Inc.

Lake Jackson, Texas, United States

Site Status

South Texas Research Alliance LLC

Laredo, Texas, United States

Site Status

Research Across America

Plano, Texas, United States

Site Status

Advanced Clinical Research

West Jordon, Utah, United States

Site Status

Health Research of Hampton Roads, Inc.

Newport News, Virginia, United States

Site Status

Krankenhaus der Elisabethinen

Graz, , Austria

Site Status

Bezirkskrankenhaus Kufstein

Kufstein, , Austria

Site Status

A. ö. Krankenhaus der Elisabethinen Linz

Linz, , Austria

Site Status

Clin Pharm International GmbH, Zentrum Wien

Vienna, , Austria

Site Status

Consultório Dr. Marcelo Rates

Belo Horizonte, , Brazil

Site Status

Instituto de Otorrinolaringologia Linhares

Rio de Janeiro, , Brazil

Site Status

Hospital de Clinicas de Porto Alegre

Rio Grande, , Brazil

Site Status

Faculdade de Medicina do ABC

Santo André/SP, , Brazil

Site Status

Universidade Federal de São Paulo - UNIFESP

Sao Paulo/ SP, , Brazil

Site Status

Instituto Ganz Sanchez

São Paulo/SP, , Brazil

Site Status

Clínica OTOSUL

Valença, , Brazil

Site Status

Klin. Forschung Berlin Buch GmbH

Berlin, , Germany

Site Status

Praxis im Schlosscarree

Braunschweig, , Germany

Site Status

Dr. Klaus Peter Jayme

Darmstadt, , Germany

Site Status

Dr. Christian Dörr

Dresden, , Germany

Site Status

Dr. Elisabeth Kühne

Halle, , Germany

Site Status

Dr. Werner Gieselmann

Heiligenhaus, , Germany

Site Status

Dr. Wolfgang Lotte

Iserlohn, , Germany

Site Status

ClinPharm International GmbH

Leipzig, , Germany

Site Status

HNO Praxis, Bamberger Str. 7

Lichtenfels, , Germany

Site Status

Dr. Dannesberger

Lorsch, , Germany

Site Status

LMU München, Klinikum Großhadern

München, , Germany

Site Status

Dr. Susanne Wiedemann

Nuremberg, , Germany

Site Status

Instituto Biomédico de Investigación A.C.

Aguascalientes, , Mexico

Site Status

Hospital General de Chihuahua

Chihuahua City, , Mexico

Site Status

Hospital Christus Muguerza del Parque

Chihuahua City, , Mexico

Site Status

Clinical Research Instutute S.C.

Edo. de México, , Mexico

Site Status

Hospital Civil de Guadalajara "Fray Antonio Alcalde", Servicio de Otorrinolaringología; Hospital No. 278

Guadalajara Jalisco, , Mexico

Site Status

Grupo Médico Terranova

Guadalajara Jalisco, , Mexico

Site Status

Unidad de Investigación Clínica Cardiometábolica de Occidente S.C. (UNICAMO)

Jalisco, , Mexico

Site Status

Hospital General de México S.S. O.D.; Servicio de Otorrinolaringología

México D.F., , Mexico

Site Status

Hospital OCA Monterrey International Research Center (MIRC)

Nuevo León, , Mexico

Site Status

Hospital Universitario

Nuevo León, , Mexico

Site Status

Unidad de Tratamientos Avanzados (UTRAV) S.C.

Nuevo León, , Mexico

Site Status

Hospital Central "Dr. Ignacio Morones Prieto"; Servicio de Otorrinolaringología

San Luis Potosí City, , Mexico

Site Status

Medicentro del Parque

San Luis Potosí City, , Mexico

Site Status

Unidad Médica de Especialidades del Noroeste (UMEN)

Sinaloa, , Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Argentina United States Austria Brazil Germany Mexico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-011246-25

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MRZ 92579/TI/3003

Identifier Type: -

Identifier Source: org_study_id